 CAMBRIDGE, Mass., Jan. 03, 2023 GLOBE NEWSWIRE -- Vigil Neuroscience, Inc. Nasdaq: VIGL, a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 8:15 a.m. PT 11:15 a.m. ET. 